Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2011

Open Access 01-12-2011 | Short report

Expression and distribution of PPP2R5C gene in leukemia

Authors: Haitao Zheng, Yu Chen, Shaohua Chen, Yuzhe Niu, Lijian Yang, Bo Li, Yuhong Lu, Suxia Geng, Xin Du, Yangqiu Li

Published in: Journal of Hematology & Oncology | Issue 1/2011

Login to get access

Abstract

Background

Recently, we clarified at the molecular level novel chromosomal translocation t(14;14)(q11;q32) in a case of Sézary syndrome, which caused a rearrangement from TRAJ7 to the PPP2R5C gene. PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A). It plays a crucial role in cell proliferation, differentiation, and transformation. To characterize the expression and distribution of five different transcript variants of the PPP2R5C gene in leukemia, we analyzed the expression level of PPP2R5C in peripheral blood mononuclear cells from 77 patients with de novo leukemia, 26 patients with leukemia in complete remission (CR), and 20 healthy individuals by real-time PCR and identified the different variants of PPP2R5C by RT-PCR.

Findings

Significantly higher expression of PPP2R5C was found in AML, CML, T-ALL, and B-CLL groups in comparison with healthy controls. High expression of PPP2R5C was detected in the B-ALL group; however, no significant difference was found compared with the healthy group. The expression level of PPP2R5C in the CML-CR group decreased significantly compared with that in the de novo CML group and was not significantly different from the level in the healthy group. By using different primer pairs that covered different exons, five transcript variants of PPP2R5C could be identified. All variants could be detected in healthy samples as well as in all the leukemia samples, and similar frequencies and distributions of PPP2R5C were indicated.

Conclusions

Overexpression of PPP2R5C in T-cell malignancy as well as in myeloid leukemia cells might relate to its proliferation and differentiation. Investigation of the effect of target inhibition of this gene might be beneficial to further characterization of molecular mechanisms and targeted therapy in leukemia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bacher U, Kohlmann A, Haferlach T: Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev. 2010, 36: 637-646. 10.1016/j.ctrv.2010.05.002.CrossRefPubMed Bacher U, Kohlmann A, Haferlach T: Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev. 2010, 36: 637-646. 10.1016/j.ctrv.2010.05.002.CrossRefPubMed
2.
go back to reference Braoudaki M, Papathanassiou C, Katsibardi K, Tourkadoni N, Karamolegou K, Tzortzatou-Stathopoulou F: The frequency of NPM1 mutations in childhood acute myeloid leukaemia. J Hematol Oncol. 2010, 3: 41-10.1186/1756-8722-3-41.PubMedCentralCrossRefPubMed Braoudaki M, Papathanassiou C, Katsibardi K, Tourkadoni N, Karamolegou K, Tzortzatou-Stathopoulou F: The frequency of NPM1 mutations in childhood acute myeloid leukaemia. J Hematol Oncol. 2010, 3: 41-10.1186/1756-8722-3-41.PubMedCentralCrossRefPubMed
3.
go back to reference Zhu X, Ma Y, Liu D: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010, 3: 17-10.1186/1756-8722-3-17.PubMedCentralCrossRefPubMed Zhu X, Ma Y, Liu D: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010, 3: 17-10.1186/1756-8722-3-17.PubMedCentralCrossRefPubMed
4.
go back to reference Muneer S, Ramalingam V, Wyatt R, Schultz RA, Minna JD, Kamibayashi C: Genomic organization and mapping of the gene encoding the PP2A B56gamma regulatory subunit. Genomics. 2002, 79: 344-348. 10.1006/geno.2002.6721.CrossRefPubMed Muneer S, Ramalingam V, Wyatt R, Schultz RA, Minna JD, Kamibayashi C: Genomic organization and mapping of the gene encoding the PP2A B56gamma regulatory subunit. Genomics. 2002, 79: 344-348. 10.1006/geno.2002.6721.CrossRefPubMed
5.
go back to reference Lee TY, Lai TY, Lin SC, Wu CW, Ni IF, Yang YS, Hung LY, Law BK, Chiang CW: The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem. 2010, 285: 21567-21580. 10.1074/jbc.M109.094953.PubMedCentralCrossRefPubMed Lee TY, Lai TY, Lin SC, Wu CW, Ni IF, Yang YS, Hung LY, Law BK, Chiang CW: The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem. 2010, 285: 21567-21580. 10.1074/jbc.M109.094953.PubMedCentralCrossRefPubMed
6.
go back to reference Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008, 28: 448-456. 10.1128/MCB.00983-07.PubMedCentralCrossRefPubMed Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008, 28: 448-456. 10.1128/MCB.00983-07.PubMedCentralCrossRefPubMed
7.
go back to reference Shouse GP, Nobumori Y, Liu X: A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene. 2010, 29: 3933-3941. 10.1038/onc.2010.161.PubMedCentralCrossRefPubMed Shouse GP, Nobumori Y, Liu X: A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene. 2010, 29: 3933-3941. 10.1038/onc.2010.161.PubMedCentralCrossRefPubMed
8.
go back to reference Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y: Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2010, 3: 44-10.1186/1756-8722-3-44.PubMedCentralCrossRefPubMed Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y: Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2010, 3: 44-10.1186/1756-8722-3-44.PubMedCentralCrossRefPubMed
9.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
10.
go back to reference Wang L, Zhu K, Zha X, Chen S, Yang L, Chen S, Li Y: Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol. 2010, 3: 14-10.1186/1756-8722-3-14.PubMedCentralCrossRefPubMed Wang L, Zhu K, Zha X, Chen S, Yang L, Chen S, Li Y: Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol. 2010, 3: 14-10.1186/1756-8722-3-14.PubMedCentralCrossRefPubMed
11.
go back to reference Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood. 2006, 107: 4500-4507. 10.1182/blood-2005-09-3801.CrossRefPubMed Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood. 2006, 107: 4500-4507. 10.1182/blood-2005-09-3801.CrossRefPubMed
12.
go back to reference Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Aurén J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT: Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol. 2008, 80: 201-207. 10.1111/j.1600-0609.2007.01009.x.CrossRefPubMed Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Aurén J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT: Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol. 2008, 80: 201-207. 10.1111/j.1600-0609.2007.01009.x.CrossRefPubMed
13.
go back to reference Fält S, Merup M, Gahrton G, Lambert B, Wennborg A: Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol. 2005, 33: 883-893. 10.1016/j.exphem.2005.05.007.CrossRefPubMed Fält S, Merup M, Gahrton G, Lambert B, Wennborg A: Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol. 2005, 33: 883-893. 10.1016/j.exphem.2005.05.007.CrossRefPubMed
Metadata
Title
Expression and distribution of PPP2R5C gene in leukemia
Authors
Haitao Zheng
Yu Chen
Shaohua Chen
Yuzhe Niu
Lijian Yang
Bo Li
Yuhong Lu
Suxia Geng
Xin Du
Yangqiu Li
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-4-21

Other articles of this Issue 1/2011

Journal of Hematology & Oncology 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine